Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP13 SAD/MAD in Healthy Male Subjects
NCT03046589Phase 1Completed
- Sponsor
- Damian Pharma AG
- Start
- Mar 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dexfadrostat in primary aldosteronism (PA) and hypertension (HTN) (6 arms), sponsored by Damian Pharma AG. Primary endpoints: Safety and Tolerability and Aldosterone suppression. Started Mar 2017; status: completed.
02
Drugs
dexfadrostat
03
Conditions
primary aldosteronism (PA)hypertension (HTN)
Beyond the preview
Go deeper on NCT03046589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046589.